Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the feed-them-social domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/itdunair/public_html/itd/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the mfn-opts domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/itdunair/public_html/itd/wp-includes/functions.php on line 6121
Guest Lecture Prof Ikuo Shoji, MD., Ph.D The Current Therapy of HBV and HCV – Institute of Tropical Disease

Guest Lecture Prof Ikuo Shoji, MD., Ph.D The Current Therapy of HBV and HCV

•Hepatitis is an inflammation of the liver that is caused by a variety of infectious viruses and noninfectious agents leading to a range of health problems, some of which can be fatal. There are five main strains of the hepatitis virus, referred to as types A, B, C, D, and E.

•While they all cause liver disease, they differ in important ways including modes of transmission, severity of the illness, geographical distribution, and prevention methods. In particular, types B and C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer, and viral hepatitis-related deaths.

•An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach. Some types of hepatitis are preventable through vaccination. A WHO study found that an estimated 4.5 million premature deaths could be prevented in low- and middle-income countries by 2030 through vaccination, diagnostic tests, medicines, and education campaigns. WHO’s global hepatitis strategy, endorsed by all WHO Member States, aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030.

Berita lainnya

Archives
PHP Code Snippets Powered By : XYZScripts.com

Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /home/itdunair/public_html/itd/wp-includes/functions.php on line 5471

Notice: ob_end_flush(): failed to send buffer of zlib output compression (1) in /home/itdunair/public_html/itd/wp-includes/functions.php on line 5471